New RSV drug for babies shows promise in phase 3 trial
NCT ID NCT07402512
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests an oral medicine called deurremidevir in infants and young children (1 month to 3 years old) with RSV infection. The goal is to see if it can shorten the time until symptoms like wheezing and rapid breathing go away. About 498 children will receive either the drug or a placebo for 5 days. If successful, it could offer a new way to help babies recover faster from RSV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deurremidevir hydrobromide (oral suspension)
What this could lead to
If it works, this could provide a fast-acting treatment to ease RSV symptoms in infants and young children, reducing hospital stays and breathing distress.
What could go wrong
This is still a placebo-controlled trial, so the drug may not prove better than placebo. Side effects in very young children are unknown, and results may not apply to all RSV cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Children's Hospital
RECRUITINGChangsha, Hunan, China
Contact Email: •••••@•••••
-
Shulan(hangzhou)Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital Of Xiamen University
RECRUITINGXiamen, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Second University Hospital Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••